Press releases
These press releases are intended for journalists and analysts/investors.
-
Ovarian Cancer Therapy Zejula Newly Funded by Government
GSK Australia welcomes the Pharmaceutical Benefits Schedule (PBS) funding of niraparib.
-
Record number of sales roles open across the country at GSK Australia
Over 30 sales roles are currently open at GSK Australia, as the business continues on its exciting growth journey.
-
GSK Australia continues bridging skills gap between academic and industry with new cohort of Graduate Researchers
GSK Australia is delighted to announce the second year of its Graduate Researcher Program.
-
Enhanced parental leave policy increases support for working parents at GSK Australia and New Zealand
GSK Australia and New Zealand is proud to share the next evolution of its parental leave policy that ensures benefits
-
TRELEGY® ELLIPTA® listed on PBS for severe asthma
Single inhaler triple therapy for severe asthma reimbursed by the PBS in Australia
-
GSK Australia supports the Australian Red Cross Queensland and New South Wales Flood Appeal
GSK Australia supports the Australian Red Cross Queensland and New South Wales Flood Appeal
-
GSK & ViiV Healthcare: Our commitment to all LGBT+ communities
GSK & ViiV Healthcare: Our commitment to all LGBT+ communities
-
TGA approves Zejula for ovarian cancer providing another option for newly diagnosed women with this deadly disease
GSK Australia welcomes the Therapeutic Goods Administration (TGA) registration of niraparib.
-
Global innovation in intensive care research wins Australian duo GSK Award for Research Excellence
The 2021 GSK Award for Research Excellence was presented at Research Australia’s Health and Medical Research Awards in Sydney.
-
GSK Australia Celebrate Launch of Reconciliation Action Plan
We seek to listen, learn and engage with Aboriginal and Torres Strait Islander peoples to play our part in Australian Reconciliation.
-
Experts map “post-jab” future in GSK-sponsored panel discussion
Today’s discussion was the first in a series of three sessions that will focus on Australia’s post-pandemic future, convened by CEDA.
-
New campaign launched to raise awareness of shingles
Experts are rallying to help the community learn more about shingles via a new campaign to raise awareness of the viral disease.
-
First monoclonal antibody treatment approved for COVID-19 in Australia
GSK Australia and Vir Biotechnology have today welcomed the Therapeutic Goods Administration (TGA) provisional approval of sotrovimab.
-
New shingles vaccine now available in Australia, June 2021
GSK Australia today announced that a new vaccine to help protect against shingles in adults aged 50 years and older
-
GSK Australia reports 2020 results to ASIC, May 2021
GlaxoSmithKline (GSK) Australia has reported its 2020 results to the Australian Securities and Investment Commission
-
GSK and ViiV Support the Uluru Statement from the Heart
GSK and ViiV are also proud to support the From the Heart campaign to raise awareness and understanding of the Uluru Statement
-
Triathlete turned scientist wins major research award for uncovering potential obesity and diabetes treatment
Professor Mark Febbraio wins the GSK Award for Research Excellence in 2020
-
Following decision announced in July, GSK confirms Boronia manufacturing site to close at end of 2022
In July, GSK announced to employees and stakeholders that the Boronia site would exit the GSK manufacturing network
-
GSK welcomes new Meningococcal B program to help protect those most at risk
GSK welcomed the addition of Meningococcal vaccination for Aboriginal and Torres Strait Islander infants to National Immunisation Program
-
Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)
GSK announced that a new pre-filled pen for the self-administration of its targeted therapy for severe eosinophilic asthma patients
